and standard temperature, and the type of surface for which it is valid;

- (4) The effect on landing distances of operation on other than smooth hard surfaces, when dry, determined under SC 23.45(g); and
- (5) The effect on landing distances of runway slope and 50 percent of the headwind component and 150 percent of the tailwind component.
  - (b) Not applicable.
  - (c) Not applicable.
- (d) In addition to paragraph (a) of this section the following information must be furnished—
- (1) The accelerate-stop distance determined under SC 23.55;
- (2) The takeoff distance determined under SC 23.59(a);
- (3) At the option of the applicant, the takeoff run determined under SC 23.59(b);
- (4) The effect on accelerate-stop distance, takeoff distance and, if determined, takeoff run, of operation on other than smooth hard surfaces, when dry, determined under SC 23.45(g);
- (5) The effect on accelerate-stop distance, takeoff distance, and if determined, takeoff run, of runway slope and 50 percent of the headwind component and 150 percent of the tailwind component;
- (6) The net takeoff flight path determined under SC 23.61(b);
- (7) The enroute gradient of climb/ descent with one engine inoperative, determined under § 23.69(b);
- (8) The effect, on the net takeoff flight path and on the enroute gradient of climb/descent with one engine inoperative, of 50 percent of the headwind component and 150 percent of the tailwind component;
- (9) Overweight landing performance information (determined by extrapolation and computed for the range of weights between the maximum landing and maximum takeoff weights) as follows—
- (i) The maximum weight for each airport altitude and ambient temperature at which the airplane complies with the climb requirements of SC 23.63(d)(2); and
- (ii) The landing distance determined under § 23.75 for each airport altitude and standard temperature.
- (10) The relationship between IAS and CAS determined in accordance with § 23.1323 (b) and (c).
- (11) The altimeter system calibration required by  $\S 23.1325(e)$ .

Issued in Kansas City, Missouri on March 23, 2007.

#### Kim Smith,

Manager, Small Airplane Directorate, Aircraft Certification Service.

[FR Doc. E7–5951 Filed 3–29–07; 8:45 am] BILLING CODE 4910–13–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

## **Food and Drug Administration**

## 21 CFR Part 310

[Docket No. 2007N-0099]

# New Drugs Exempted From Prescription-Dispensing Requirements; Technical Amendment

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule; technical amendment.

SUMMARY: Amendments to the Federal Food, Drug, and Cosmetic Act (the act) necessitate several changes to the citations used in Food and Drug Administration (FDA) regulations regarding the prescription-exemption procedure and the list of new drugs that are exempted from the prescription-dispensing requirements. These changes are editorial, pertaining only to citations, and do not constitute a change in FDA regulation.

**DATES:** This rule is effective March 30, 2007.

# FOR FURTHER INFORMATION CONTACT:

Gerald M. Rachanow, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 22, rm. 5496, Silver Spring, MD 20993, 301–796– 2090.

**SUPPLEMENTARY INFORMATION: Section** 126 of the Food and Drug Administration Modernization Act of 1997 (FDAMA) (Public Law 105-115) amended section 503(b)(1) of the act (21 U.S.C. 353(b)(1)). Specifically, the previous paragraph (b)(1)(A) of the act was stricken from the act and paragraphs (b)(1)(B) and (b)(1)(C) were redesignated as paragraphs (b)(1)(A) and (b)(1)(B), respectively. This amendment to the act necessitates that FDA revise the corresponding citations in its regulations. FDA is making this change in 21 CFR part 310 (§§ 310.200 and 310.201). These changes are editorial, pertaining only to citations, and do not constitute a change in FDA regulation.

Publication of this document constitutes final action on this change under the Administrative Procedure Act (5 U.S.C. 553). Notice and public procedures are unnecessary because FDA is merely implementing a change in citation to a section of the act as a result of amendment of the act.

## List of Subjects in 21 CFR Part 310

Administrative practice and procedure, Drugs, Labeling, Medical devices, Reporting and recordkeeping requirements.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs, 21 CFR part 310 is amended as follows:

# **PART 310—NEW DRUGS**

■ 1. The authority citation for 21 CFR part 310 continues to read as follows:

**Authority:** 21 U.S.C. 321, 331, 351, 352, 353, 355, 360b–360f, 360j, 361(a), 371, 374, 375, 379e; 42 U.S.C. 216, 241, 242(a), 262, 263b–263n.

#### §310.200 [Amended]

■ 2. In § 310.200(a), (b), and (e) remove "503(b)(1)(C)" wherever it appears and add in its place "503(b)(1)(B)".

#### §310.201 [Amended]

■ 3. In § 310.201(a) remove "503(b)(1)(C)" and add in its place "503(b)(1)(B)".

Dated: March 22, 2007.

# Jeffrey Shuren,

Assistant Commissioner for Policy. [FR Doc. E7–5895 Filed 3–29–07; 8:45 am] BILLING CODE 4160–01–S

#### **DEPARTMENT OF THE TREASURY**

## **Internal Revenue Service**

# 26 CFR Part 1

[TD 9320]

RIN 1545-BF67

# United States Dollar Approximate Separate Transactions Method

**AGENCY:** Internal Revenue Service (IRS), Treasury.

**ACTION:** Final regulation.

**SUMMARY:** This document contains final regulations which provide the translation rates that must be used when translating into dollars certain items and amounts transferred by a qualified business unit (QBU) to its home office or parent corporation for purposes of computing dollar approximate separate transactions method (DASTM) gain or loss. This regulation is necessary to provide guidance under section 985